## **Core Concept**
Kostmann's syndrome, also known as severe congenital neutropenia, is a rare, inherited disorder characterized by a significant reduction in the production of neutrophils, a type of white blood cell crucial for fighting infections. The condition results from mutations in the HAX1 gene, leading to impaired neutrophil production. Treatment aims to stimulate neutrophil production or mitigate the risk of infections.

## **Why the Correct Answer is Right**
The correct answer involves **Granulocyte-Colony Stimulating Factor (G-CSF)**, which is a type of growth factor that stimulates the bone marrow to produce granulocytes and stem cells, and then release them into the bloodstream. G-CSF is specifically used to treat conditions like Kostmann's syndrome by directly addressing the underlying cause of neutropenia, i.e., the insufficient production of neutrophils.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because, although antibiotics may be used to manage infections in patients with Kostmann's syndrome, they do not address the underlying cause of the condition, which is the reduced production of neutrophils.
- **Option B:** This option is incorrect as it does not directly relate to the established treatment for Kostmann's syndrome.
- **Option D:** This option is incorrect because, similar to antibiotics, other growth factors might have some effect on blood cell production but are not the primary treatment for Kostmann's syndrome.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl for Kostmann's syndrome is that patients require **prophylactic antibiotics** and **G-CSF therapy** to manage their condition effectively. The introduction of G-CSF has significantly improved the prognosis for individuals with this syndrome, reducing the risk of life-threatening infections.

## **Correct Answer Line**
**Correct Answer: C. G-CSF.**